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Abstract: Effective treatment with etanercept results from a congregation of immunological 
signaling and modulating roles played by tumor necrosis factor-alpha (TNF-alpha), a pervasive 
member of the TNF super-family of cytokines participating in numerous immunologic and 
metabolic functions. Macrophages, lymphocytes and other cells produce TNF as part of the 
deregulated immune response resulting in psoriasis or other chronic inﬂ  ammatory disorders. 
Tumor necrosis factor is also produced by macrophages and lymphocytes responding to foreign 
antigens as a primary response to potential infection. Interference with cytokine signaling by 
etanercept yields therapeutic response. At the same time, interference with cytokine signaling by 
etanercept exposes patients to potential adverse events. While the efﬁ  cacy of etanercept for the 
treatment of psoriasis is evident, the risks of treatment continue to be deﬁ  ned. Of the potential 
serious adverse events, response to infection is the best characterized in terms of physiology, 
incidence, and management. Rare but serious events: activation of latent tuberculosis, multiple 
sclerosis, lymphoma, and others, have been observed but have questionable or yet to be deﬁ  ned 
association with therapeutic uses of etanercept. The safe use of etanercept for the treatment of 
psoriasis requires an appreciation of potential adverse events as well as screening and monitoring 
strategies designed to manage patient risk
Keywords: etanercept, psoriasis, demyelination, tumor necrosis factor, lymphoma, tuberculosis, 
infection, safety
Characterizing the safety of a drug is rarely simple and never complete. Both short 
and long-term drug safety proﬁ  les require episodic, critical reviews of available 
information. Episodic reviews are necessary to survey case reports and put previous 
summaries into perspective. Critical evaluation is important to determine relevance, 
veracity, and adequacy of available information. Etanercept is no exception.
The short-term safety of etanercept is well established by rigorous clinical trials in 
rheumatoid arthritis, psoriatic arthritis, and psoriasis (Leonardi et al 2003; Papp 2004; 
Keystone 2005; Kavanaugh et al 2006). Registries, now abundant in the rheumatology 
arena, are resources for assessing long-term risk and harm (Sokka 2004). Psoriasis 
registries should provide useful data over the next few years. Nonetheless, information 
extracted from registries must be put into context. The underlying disease may have 
epidemiologic characteristics different from the target disease. And, by their nature, 
registries are not as restrictive or as selective as controlled trials (Krishnan and Fries 
2004). There is a treatment bias: treatment tends to be given to a sicker population. 
There may be a confounding indication: not every enrollee fulﬁ  lls appropriate 
diagnostic criteria. Biased patient selection, good or bad, may exaggerate effectiveness 
or safety. In addition, patients enrolled in clinical registries have few if any restriction on 
concurrent therapy thus confounding drug-drug interactions and attribution of efﬁ  cacy 
or adverse effects. On the other hand, registries are thought to be more reﬂ  ective of Therapeutics and Clinical Risk Management 2007:3(2) 246
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real world experience. In addition, registries often provide 
larger number of patients, long periods of observation and 
data collection compared with registration trials.
Case reports will identify unanticipated adverse events 
attributed to etanercept but are limited by the potential for 
inappropriate association of cause and effect. Etanercept is an 
effective therapy for psoriasis: effectiveness is advantageous 
to its adoption as a new therapy. This advantage is potentially 
offset by heightened scrutiny, off-label use, and sub-standard 
post marketing reports of adverse events.
In this review, every effort is made to provide a balanced 
appraisal of risk. Pathophysiology and likelihood of 
association are considered as complements to incident reports 
when evaluating safety (Mulrow et al 1997; Ioannidis et al 
2006). Where assessment of risk is hampered by insufﬁ  cient 
epidemiologic data, provisional estimates or cautionary 
comments are inserted.
Background
TNF-alpha, often referred to as tumor necrosis factor (TNF), 
is one member of the TNF superfamily of cytokines (Zhou 
et al 2002). TNF was initially described as a hemorrhagic 
necrosis factor produced by lipopolysaccharide-stimulated 
tumours. We now appreciated that TNF is a ubiquitous 
cytokine expressed by many cell types and having activity 
in innate and adaptive immune pathways (Zhou et al 2002). 
As a consequence of its important immunological function, 
TNF plays a central role in acute and chronic inﬂ  ammation 
(Liz-Grana and Carnota 2001; Pfeffer, 2003). The variety 
of immunological and metabolic processes affected by 
TNF-alpha, the functions of soluble and membrane bound 
TNF-alpha, and interactions between members of the TNF 
superfamily are impacted by the molecular activity of TNF-
inhibitors such as etanercept. Both unanticipated risks and 
unanticipated beneﬁ  ts may arise through long-term high 
frequency exposure to a TNF-inhibitor. Given the unique 
molecular characteristics of each TNF-inhibitor, we expect 
common risk-beneﬁ  t proﬁ  les and differences. 
Etanercept is a dimeric fusion protein produced using 
recombinant genetic programming of Chinese hamster ovary 
cells. The protein has a molecular weight of 150 kDa and 
consists of two 75 kDa TNF-alpha receptors linked to the Fc 
portion of human immunoglobulin G1 (Dembic et al 1990; 
Mohler et al 1993).
Clinical study reports are sufﬁ  ciently detailed to provide 
short term safety data, but none are powered to identify rare 
events. The National Data Bank for Rheumatic Diseases 
and the publicly available BIOBADASER are examples of 
registries that provide excellent longitudinal information 
on patients with rheumatologic diseases treated with TNF-
antagonists.
The structure of this review is as follows: Broad 
categories of adverse events are identiﬁ  ed. Within each 
category there may be speciﬁ  c, noteworthy concerns. Inciting 
observations and scientiﬁ  c rationale preface each general and 
speciﬁ  c category. Data relevant to the category are presented 
accompanied by brief commentary. Comparative data for 
TNF-antagonists as a group are avoided where possible to 
limit the scope of the review.
Mechanisms of action
Tumor necrosis factor-alpha engages in many aspect of 
immunological function. By its activity on TNF-alpha, 
etanercept will impact immunological and inﬂ  ammatory 
processes ranging from innate and extrinsic immunological 
response, cellular trafﬁ  cking, acute and chronic inﬂ  ammation, 
fever, and neuroendocrine regulation (Gruss and Dower 
1995). TNF interacts with glucocorticoids to regulate Toll-
like receptor 2 gene expression (Hermoso et al 2004). 
The precise mechanisms of action of TNF-antagonists 
are not known. Certainly etanercept binds to free, soluble, 
or non-membrane-bound TNF-alpha but etanercept also 
has activity against the p55 receptor TNF-beta, also called 
lymphotoxin (Williams and Grifﬁ  ths 2002; Keystone and 
Dinarello 2005). Contrary to the effects on TNF-alpha, the 
activity of etanercept against p55 may stimulate immuno-
reactivity (Han et al 2005) in addition to having effects on B-, 
T-, NK-cells and lymphoid architecture (Spahn et al 2005). 
Moreover, there is evidence that both etanercept and inﬂ  iximab 
induce apoptosis in macrophages, but not lymphocytes within 
rheumatoid arthritis (RA) joints (Catrina et al 2005). In general, 
the effects of etanercept are mediated by its binding of soluble 
TNF-alpha, but other TNF-antagonist activities are recognized. 
The implications of accessory TNF-antagonist activities are 
not known. Etanercept has peak absorption at 51 hours and a 
mean half-life of 68 hours (Korth-Bradley et al 2000).
Whether or not TNF is an intrinsic pyrogen remains 
controversial (Stefferl et al 1996; Luheshi et al 1997; 
Dinarello 2005). In the mouse model, TNF does not appear 
to have pyrogen activity (Dinarello 2005). Nonetheless, 
resolving the question for humans is signiﬁ  cant as fever is a 
common, early, ubiquitous sign of infection and infections 
remain the most prominent safety concern during treatment 
with TNF-antagonists.Therapeutics and Clinical Risk Management 2007:3(2) 247
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A more complex role is reﬂ  ected in the effects TNF may have 
on neuroendocrine response. Pituitary and hypothalamic response 
are potentiated when TNF is present in high levels (Turnbull 
and Rivier 1999). The neuroendocrine effects of TNF may be 
reﬂ  ected in the psychological state of patients experiencing 
chronic inﬂ  ammatory disease (Tyring et al 2006).
Adverse events
Injection site reactions
Mechanical processes such as poor injection technique, 
irritation, or immunologically mediated inflammatory 
processes associated with either drug or excipients cause 
injection site reactions. Foreign proteins may cause direct 
or indirect inﬂ  ammatory response (Shepherd 2003). It is not 
surprising that injection site reactions are by far the most 
common side effect associated with etanercept. 
Studies evaluating etanercept for the treatment of RA 
report a high incidence of injection site reactions with 
34%–37% of etanercept-treated patients compared with 
7%–10% of controls reporting reactions (Lebwohl 2002; 
Fleischmann and Yocum 2004). The high incidence in the 
RA population contrasts with a much lower incidence seen 
in psoriasis studies: 14%–20% (Leonardi et al 2003; Papp 
2004; Papp et al 2005). Why there are stark differences in 
the incidence of injection site reactions between RA and 
psoriasis populations is not known.
Injection site reactions with 25 mg doses of etanercept 
are mild, well tolerated, self-limiting, and tend to occur early 
in the course of therapy (Zeltser et al 2001; Papp 2004). 
Irritation during and brieﬂ  y following injection is very 
common with the 50 mg single dose compared with the 25 
mg dosing formulation. Occasionally, persistent reactions 
of moderate severity are noted. Persistent reactions are 
characterized by erythematous, indurated, and urticarial like 
plaques (Edwards et al 2003). The histology of etanercept 
injection site reactions is consistent with a delayed-type 
hypersensitivity reaction (Werth and Levinson 2001; Zeltser 
et al 2001). Delayed and recall injection site reactions are 
infrequent but tend to be somewhat more severe than typical 
etanercept-associated injection site reactions (Zeltser et al 
2001; Rajakulendran and Deighton 2004). Signiﬁ  cant 
and severe injection site reactions are rare with etanercept 
regardless of dose (Papp 2004).
Infection
Clinical trials and post-marketing experience suggest that 
infection is the most common signiﬁ  cant category of adverse 
events experienced by patients treated with etanercept. Less 
common infections including tuberculosis and opportunistic 
infections, speciﬁ  cally histoplasmosis and listeriosis, are 
considered separately.
TNF is involved in the immune response to bacterial 
and viral infections (Imanishi 2000; Herbein and O’Brien 
2000). More speciﬁ  cally, TNF plays an essential role in 
host response to intracellular pathogens (Choy and Panayi 
2001). The important role of TNF in immune response to 
intracellular organisms is further supported by TNF-deﬁ  cient 
animal models (Marino et al 1997). For Gram-positive and 
Gram-negative infections, clearance of organisms may 
be impeded by TNF-suppression (Takashima et al 1997; 
O’Brien et al 1999; Rijneveld et al 2003; Moore et al 2003, 
2005). Clinical studies, registries, and case reports conﬁ  rm 
that host response to infection is the most common signiﬁ  cant 
safety concern in patients treated with etanercept.
Serious infection is deﬁ  ned within studies and for safety 
monitoring as one requiring intravenous antibiotics or 
hospitalization (Keystone 2004). The incidence of serious 
infections in patients treated with etanercept varies according 
to the population treated, severity of disease, concomitant 
medication, and adherence to a deﬁ  nition of serious infection. 
Some report serious infections as those requiring systemic 
therapy. 
During the clinical trial development of etanercept, the 
observed serious infection rate in the RA population was 
0.03–0.04 serious infectious events per patient-year (SIE/
pt-yr), equal to rates seen in placebo controls (Cush 2004a 
2004b). Post-marketing surveillance across all indicated 
diseases has shown the rates of SIE with etanercept and 
inﬂ  iximab to be 0.007 SIE/pt-yr (conﬁ  dence interval [CI] 
0.03–0.09/pt-yr). Signiﬁ  cant under-reporting with post-
marketing surveillance is expected but confounding effects 
include a less well deﬁ  ned treated population, inclusion of 
indications other than those reported in the clinical studies, 
and thus these rates may be substantially more common in 
the RA population (Cush 2004a, 2004b).
Within the RA population, an increased risk of 
serious infection is seen in patients having extra-articular 
manifestations of RA, presence of comorbid diseases, and 
immunosuppressive therapy (Doran et al 2002a). These 
infections tend to be upper respiratory, skin, and urinary 
tract infections.
Tumor necrosis factor-antagonist therapy may increase 
the risk of infection in the RA population. Reports of 
the number of infection-related adverse events per 100 Therapeutics and Clinical Risk Management 2007:3(2) 248
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patient-years during an 18 month period show that etanercept 
had a rate of 22.6 (18.7–27.2) events per hundred years 
compared with controls (those receiving disease modifying 
and remitting drugs [DMARDs]) with a rate of 6.8 (5.0–9.4) 
per hundred patient years (Listing et al 2005). The rates 
for serious infections were 6.4 (4.5–9.1) and 2.3 (1.3–3.9) 
for etanercept and control groups respectively. Adjusting for 
case-patient mix, the rates of serious infection were similar 
for etanercept and inﬂ  iximab. These results suggest there 
is an increased risk of infection in those treated with TNF-
antagonists. This study is limited by small numbers, a short 
observation period, and bias in populations: those on anti-
TNF cannot be the same population as those on DMARDs 
since general patients with more severe disease are treated 
with TNF-antagonists, which introduces potential bias in the 
study populations. 
It is certain that TNF-antagonists exacerbate septicemia 
with increase in mortality among septic patients on etanercept 
(Fisher et al 1996; Baghai et al 2001). 
Patients developing new infections while on etanercept 
should be closely monitored and discontinued in those with 
serious infections or sepsis. Etanercept should not be initiated 
in patients with active infections including chronic or local-
ized infections. Caution should be exercised when initiating 
etanercept in patients with a history of or predisposition to 
frequent recurrent infections.
Mycobacterium tuberculosis 
Susceptibility to mycobacterium tuberculosis (TB) impacted 
by multiple factors including age, environment, immune 
status, and microbial virulence (Mitsos et al 2003) and 
genetic susceptibility (Abel and Casanova 2000; Casanova 
and Abel 2002). Latent tuberculosis remains a signiﬁ  cant 
global health concern with nearly 30% of the world 
population infected (Jasmer et al 2002). TNF is necessary 
for cell recruitment, granuloma formation, and clearance of 
mycobacterial infection (Roach et al 2002). Recent clinical 
results demonstrating reactivation of latent TB in patients 
receiving anti-TNF monoclonal antibody therapy solidiﬁ  es 
the importance of TNF in host response to TB (Keane et al 
2001; Keane 2004, 2005).
The role of TNF in initial host response and subsequent 
conﬁ  nement of TB organisms is complex and not completely 
elucidated. TNF regulates chemokine induction that in turn 
orchestrates cell recruitment, granuloma formation, and 
clearance of mycobacterial infection (Roach et al 2002; 
Stenger 2005). Mice lacking TNF mount delayed chemokine 
response and cellular inﬁ  ltrate. Subsequent high chemokine 
production produced disorganized T-cell and macrophage 
responses capable of producing high levels of interferon-
gamma but unable to protect against fatal TB infections 28 
days post inoculation. Wild mouse strains survived 16 weeks 
or longer. The response of TNF-deﬁ  cient mice exposed to 
mycobacteria anticipates the prominent role TNF plays in the 
initial response to infection and subsequent maintenance of 
granulomas. In large part, mortality results from unchecked 
type-1 inﬂ  ammatory response producing tissue necrosis 
(Zganiacz et al 2004). Animal models also suggest there 
are differences in the activity of membrane-bound and -free 
TNF in acute and chronic response to TB (Olleros et al 2005; 
Saunders et al 2005). TNF is also required to maintain latency 
of TB (Botha and Ryffel 2003). Thus, the role of TNF in 
immune response to TB is poly-modal: initiate inﬂ  ammatory 
response, regulate and suppress the inﬂ  ammatory response, 
and maintain chronic immunological response.
RA patients on etanercept showed a linear incidence 
of TB infection (Wallis et al 2004a, 2004b) suggesting 
that acquisition of TB was related to exposure and not 
re-activation of latent infection. Inﬂ  iximab-treated patients 
demonstrated an accelerated incidence of TB infection in 
keeping with activation of latent disease (Wallis et al 2004a, 
2004b). While the incidence of TB in patients on etanercept 
may not be signiﬁ  cantly greater than the background rate, 
treatment with etanercept does alter the clinical presentation 
of TB (Arend et al 2003; Gardam et al 2003). Approximately 
half of patients treated with etanercept who develop clinical 
TB present with extra-pulmonary manifestations including 
disseminated TB. The expected rate of extra-pulmonary 
TB in immunocompetent hosts is less than 15% (Dye et al 
1999).
In summary, there is no scientiﬁ  c data in support of 
screening for latent TB prior to initiating therapy with 
etanercept. However, patients treated with etanercept who 
acquire infection with TB are more likely to have atypical 
presenting signs and symptoms. Etanercept-treated patients 
developing TB may be at increased risk of severe and 
potentially fatal infection. Screening for active TB with a 
chest X-ray is medically prudent. A more cautious approach 
is to screen for latent and active TB by chest X-ray (CXR) 
and tuberculin (PPD) testing prior to initiating etanercept 
in patients at high risk. Based upon minimal data, but 
highlighting the need for extreme safety, some suggest a 
CXR and PPD prior to introducing any immunosuppressive 
treatment (CDC 2004; Keane 2005). Therapeutics and Clinical Risk Management 2007:3(2) 249
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Opportunistic infections
Opportunistic infections occur in patients on TNF-blocking 
agents (Jarvis and Faulds 1999; Garrison and McDonnell 
1999; Mease et al 2000; Doran et al 2002a, 2002b; Netea 
et al 2003; Elkayam et al 2004), but these are rare (Keystone 
2004).
Histoplasmosis is an uncommon opportunistic infection 
endemic to many regions of the world (Cano and Hajjeh 
2001). Normal host defense to infection is dependent upon 
TNF expression (Smith et al 1990; Zhou et al 1998). Infection 
with histoplasmosis may be exacerbated in patients on therapy 
with TNF-antagonists, but lack of control comparators and 
cases occurring in histoplasmosis-endemic regions of the 
US make any conclusions tentative (Lee et al 2002). Less 
certain is the question of risk of reactivation of latent infection 
with histoplasmosis. This uncertainty is highlighted by 
reports of disseminated histoplasmosis occurring in patients 
on low-dose methotrexate (Berry 1969; Witty et al 1992; 
LeMense and Sahn 1994; Voloshin et al 1995; Roy and 
Hammerschmidt 2000; Arunkumar et al 2004).
Listeria monocytogenes is an uncommon but ubiquitous, 
opportunistic, intracellular pathogen causing gastroenteritis, 
meningitis, encephalitis, and septicemia (Hamon et al 
2006). TNF is essential to effect normal host response to 
listeria (Havell, 1989, Rothe et al 1993; Kanaly et al 1999; 
Dinarello 2003; Torres et al 2005) and treatment with 
etanercept may predispose patients to infection (Schett et al 
2005). Infection with listeria is reported in patients treated 
with TNF-antagonists and particularly etanercept (Slifman 
et al 2003; Ehlers 2005; La Montagna and Valentini 2005; 
Nadarajah and Pritchard 2005; Rachapalli and O’Daunt 2005; 
Schett et al 2005). What is not evident is whether there is a 
real increased risk of infection or a modiﬁ  cation of clinical 
presentation and host response (Pagliano et al 2004). Given 
that etanercept does affect lymphotoxin (Williams and 
Grifﬁ  ths 2002) and that lymphotoxin is essential in providing 
normal immune response to listeria (Ehlers et al 2003), the 
possible increased susceptibility to infection with listeria 
must be considered. 
Rare cases of disseminated sporotrichosis further stress 
the importance of TNF in maintaining normal host response 
to infections (Gottlieb et al 2003).
Vaccination
TNF plays a signiﬁ  cant role in immune response to pathogens 
(Herbein and O’Brien 2000) and may therefore modulate 
host response to vaccination. A number of studies have 
evaluated response to inﬂ  uenza vaccine in RA patients treated 
with etanercept. In general, response to inﬂ  uenza vaccine is 
blunted but not completely suppressed (Fomin et al 2006). 
The addition of methotrexate further suppresses the response 
to vaccination (Kapetanovic et al 2006). 
Malignancy exclusive of lymphoma
The role of TNF in carcinogenicity and tumor surveillance 
has not been established. Early cell culture studies indicated 
that TNF is cytotoxic for certain tumor cell lines (Old 1985; 
Creasey et al 1986; Palladino, Patton, et al 1987; Palladino, 
Srivastava, et al 1987). Subsequent studies revealed that, for 
certain types of malignancies, TNF may act as a growth factor 
(Freedman et al 1992; Warzocha et al 1995; Filella et al 1996; 
Warzocha and Salles 1998; Warzocha, Bienvenu, et al 1998; 
Warzocha, Ribero, et al 1998; Renard et al 1999; Moore 
et al 1999) and may even enhance the metastatic potential of 
certain tumors (Balkwill et al 1990; Malik et al 1990). 
Review of the clinical studies and registries for TNF-
antagonists shows no increase in the incidence of solid tumors 
in the RA population (Keystone 2003, 2005). Likewise, in 
the clinical studies evaluating etanercept for the treatment of 
psoriasis, there is no evidence of increased risk of malignancy 
(Leonardi et al 2003; Papp 2004; Papp et al 2005). The 
potential for increased risk of solid tumors in patients 
receiving concurrent etanercept and alkylating agents must 
be considered (Mukhtyar and Luqmani 2005; WGET 2005; 
Hellmich et al 2006; Stone et al 2006). There are cases of 
rapidly developing squamous cell carcinomas in RA patients 
initiating therapy with etanercept (Smith and Skelton 2001). 
To the contrary, TNF-alpha deﬁ  cient mice are resistant to 
cutaneous carcinogenesis (Arnott et al 2002).
Lymphoma
There is a strong association of non-Hodgkin’s lymphoma with 
Epstein-Barr virus (EBV) infection and immunosuppression 
(Liebowitz 1998; Meyer et al 2004; Poppema 2005). 
Approximately 95% of adults are infected with EBV. Many 
develop subclinical reactivation (Rickinson and Kieff 1996). 
Members of the TNF superfamily of receptors play a role 
in pathogenesis of EBV-positive lymphomas arising in 
immunosupressed patients, but the role of TNF-alpha is not 
established (Liebowitz 1998; Herbein and O’Brien 2000). 
Chronic inﬂ  ammation produces elevated TNF levels, which 
in turn produce indirect alterations in immunological function 
(Khan 2006; Weyand et al 2006) and modulatory effects 
of TNF on T-cell surveillance (Baran-Marszak et al 2006). Therapeutics and Clinical Risk Management 2007:3(2) 250
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Confounding the role of TNF in the develoment of lymphoma 
is the association of chronic inﬂ  ammatory processes and 
lymphoma (Kato et al 2003; Chang et al 2005). The potential 
association of TNF, TNF-antagonism, and the development 
of lymphomas is confounded by epidemiologic surveys 
showing a strong trend in risk in patients with psoriasis 
(Hannuksela-Svahn et al 2000; Gelfand et al 2003, 2006) 
though these ﬁ  ndings are not substantiated by larger surveys 
(Smedby et al 2006). The association of lymphoma and 
rheumatoid arthritis appear more certain (Baecklund et al 
1998, 2003, 2004, 2006; Ekstrom et al 2003). 
There are case reports of lymphoma developing in 
patients receiving TNF-antagonists (Brown et al 2002). Of 
the 26 cases reported, 18 developed in patients on etanercept. 
The mean time to onset of lesions after commencing therapy 
was 8 weeks. Data from an RA registry suggests an increased 
risk of lymphoma in patients treated with TNF-antagonists 
or methotrexate compared with those who are not (Wolfe 
and Michaud 2004b). There is; however, a strong selection 
bias in that those receiving anti-TNF therapy tend to be the 
most severely affected patients, a cohort already known to 
have a greater risk of lymphoma (Baecklund et al 1998) 
and that the strongest association is not with therapy but the 
underlying RA itself (Baecklund et al 2006). In addition, two 
cases of cutaneous and systemic T-cell lymphoma progressed 
rapidly after initiating TNF-blockade: one with etanercept 
and one with inﬂ  iximab (Adams et al 2004). Both cases 
were described as rapid in onset with fulminate courses: 
extensive cutaneous, and systemic involvement resulting in 
death within months of diagnosis. 
While there are numerous case reports of lymphoma 
developing in patients treated with etanercept, the relative 
risk of lymphoma remains constant for RA patients regardless 
of therapy with TNF-antagonists (Keystone 2005). The high 
incidence of lymphoma in RA patients makes risk assessment 
complex. The lower incidence of lymphoma in the psoriasis 
population may be instrumental in the assessment of risk 
associated with long-term treatment with etanercept.
Central nervous system 
demyelination events
We have some understanding of the incidence of multiple 
sclerosis (MS) in the general population: women more com-
monly affected, there are regional variations in incidence 
and prevalence (Ebers and Sadovnick, 1993, Magnano et al 
2004). Incidence in the general population is approximately 6 
per 100 000 per year with a prevalence of nearly 85/100 000. 
An increased in risk of MS is reported in individuals with 
affected ﬁ  rst degree relatives (Sadovnick et al 1993). 
MS is uncommon. Furthermore, assessments may be 
complicated as not all instances of magnetic resonance 
imaging (MRI) ﬁ  ndings consistent with demyelination are 
MS (Koller et al 2005a). Instances of chronic, inﬂ  ammatory, 
demyelinating polyneuropathy are usually peripheral, 
but may include cortical and optic nerve demyelination. 
Interestingly, MS appears to be a Th1 disorder mediated by 
cytokines including TNF and evinces many of the pathogenic 
pathways active in psoriasis (Koller et al 2005b).
The putative relationships between TNF, TNF-antagonism, 
and MS are not obvious. Many theoretical reasons support 
TNF-antagonist activity induces demyelization (Magnano 
et al 2004). Equally supportive arguments support the 
contrary: TNF-antagonism does not increase the risk of MS 
and may potentially be of therapeutic value (Magnano et al 
2004). Reporting bias of case reports (Magnano et al 2004) 
and potential association with other autoimmune diseases 
(Midgard et al 1996) confound the role of TNF-antagonist 
therapy in the onset or exacerbation of MS. 
Much of the current concern over TNF-antagonism 
and MS results from a single study evaluating lenercept; a 
p55, recombinant, soluble TNFR1 receptor protein, for the 
treatment of relapsing-remitting and secondarily progressive 
MS (LMS-UBC 1999). The study found no increase in new 
or active lesions as demonstrated on MRI. However, there 
was a signiﬁ  cant dose-related increase of attack frequency 
though not attack severity nor attack duration. The contrary 
response of MS patients treated with lenercept underscores 
the difﬁ  culty in extrapolating results from animal models. 
Antibodies to lenercept did not affect clinical response but 
did increase rate of drug clearance (Wiendl and Hohlfeld 
2002). Two cases of MS patients treated with inﬂ  iximab 
demonstrated increased MRI activity but no clinical 
worsening (van Oosten et al 1996).
The rarity of MS in psoriasis patients treated with 
etanercept is highlighted by the rarity of case reports (Sukal 
et al 2006). From the rheumatology literature, there are 
cases temporally related to TNF-suppression, some of which 
resolved upon withdrawal of treatment (Mohan et al 2001). 
MS remains rare and of uncertain causal association with 
anti-TNF therapy (Mohan et al 2001; Magnano et al 2004). 
Many but not all patients develop recurrent symptoms on 
re-challenge (Mohan et al 2001; Cisternas et al 2002). 
There is growing concern among some groups of 
neurologists who suggest pretreatment MRI scans for all Therapeutics and Clinical Risk Management 2007:3(2) 251
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patients about to receive a TNF-antagonists (Bellesi et al 
2006). Currently, etanercept should be avoided in patients 
with a personal history of any central nervous system 
demyelinating disorder and used with caution in patients 
with a family history of these disorders. Pretreatment MRI 
may be considered in patients with equivocal histories of 
neuropathy or signs or symptoms of demyelination and ﬁ  rst 
degree family histories of MS.
Hematological events
Rare cases of pancytopenia and aplastic anemia are reported 
in association with etanercept (Lebwohl 2002). A fatal 
outcome is reported in some cases (Jarvis and Faulds 1999; 
Khanna et al 2004). Nonetheless, it is important to review 
drug and medical history to exclude other potential causes 
of myelosuppression (Baumelou et al 1993; Marshall et al 
2006).
Hepatitis
TNF plays a role in host response to hepatitis B and C (Herbein 
and O’Brien 2000). With 1.8% of the world population 
infected with hepatitis C virus and 5% infected with hepatitis 
B, the potential for exacerbation of viral hepatitis associated 
with TNF-antagonist therapy is noteworthy. While TNF does 
play a role in viral hepatic infection, the importance of TNF 
in maintaining suppression of viral replication is not clear 
(Calabrese et al 2004).
Mixed reports on response of patients with hepatitis B 
treated with anti-TNF agents correlates with the natural, 
variable history of the infection (Khanna et al 2003; 
Calabrese et al 2004; Khanna et al 2004; Lok and McMahon 
2004). Nonetheless, TNF plays a primary role in sustaining a 
normal response to infection with hepatitis B (Schlaak et al 
1999; Michel et al 2003; Ostuni et al 2003). Recently, Health 
Canada issued an advisory related to possible reactivation 
of hepatitis B in patients receiving anti-TNF therapy. The 
advisory is based upon a single case report (HPB Canada 
2006). 
The mechanisms relating to reactivation of hepatitis B 
are uncertain. Equally uncertain is the association between 
treatment with TNF-antagonists or other immunosuppressant 
and hepatitis B reactivation. More likely is reaction upon drug 
discontinuation or rebound with replication of hepatitis B 
in hepatocytes upon discontinuation of immunosuppressive 
therapy (Herbein and O’Brien 2000). 
It is suggested that antiviral therapy be initiated prior to 
initiation of immunosuppressive treatment or to introduce 
antiviral therapy upon activation of hepatitis (de Franchis 
et al 2003). 
Hepatitis C appears to follow more consistent patterns of 
infection characteristic of its natural course (Calabrese et al 
2004). A small group of hepatitis C-positive RA patients 
were administered etanercept or inﬂ  iximab for periods of 
3–36 months. None of the patients showed changes in liver 
enzymes or viral loads (Zein and Zein 2002; Peterson et al 
2003).
Elevated liver enzymes may be observed in patients 
receiving anti-TNF therapy but these observations are 
confounded by medications or circumstances making the 
aetiology of elevations uncertain (Schiemann and Kellner 
2002; Khanna et al 2003, 2004).
The data currently available suggest etanerecept is 
unlikely to have negative impact and may be protective 
against morbidity associated with chronic hepatitis C 
infection. Morbidity associated with chronic infection with 
hepatitis B virus in the face of treatment with etanercept is not 
well characterized. Prudent medical practice would support 
screening for hepatitis B infection prior to commencing 
therapy with etanercept. 
Lupus-like drug reactions
Antinuclear antibodies (ANA) and anti-DNA antibodies 
develop in RA patients treated with etanercept (Watts 2000; 
De Bandt et al 2003, 2005; Haraoui and Keystone 2006). 
There also appears to be an increase in anticardiolipin 
expression in RA patients after 6 months of etanercept 
(Jonsdottir et al 2004). While serum antibodies are rarely 
associated with symptoms, there are few cases of etanercept-
induced lupus erythematosus (Cairns et al 2002; Shakoor 
et al 2002; Carlson and Rothfield 2003). In general, 
etanercept-induced lupus resolves within 6 weeks to 14 
months of discontinuation of therapy (Mohan et al 2002). 
Most frequently, the presentation has signs and symptoms 
of sub-acute cutaneous lupus (Bleumink et al 2001; Misery 
et al 2002). Overall, drug-induced lupus appears to be less 
common in patients treated with etanercept compared with 
those treated with other TNF-antagonists (Cush 2004c).
There are no surveys indicating the prevalence of ANA 
and anti-DNA antibodies in the psoriasis population and no 
data from large clinical studies or registries identifying the 
risk of autoantibody formation in psoriasis patients treated 
with etanercept. Personal experience suggests that somewhat 
less than 10% of psoriasis patients become ANA positive 
during the ﬁ  rst two or three years of treatment. While the Therapeutics and Clinical Risk Management 2007:3(2) 252
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ANA titres are in generally low: less than 1:40, higher titres 
are observed. 
Given the overall lack of association between positive 
ANA and DNA titres in the general population and those 
treated with etanercept, screening for autoantibodies prior 
to treatment with etanercept is unwarranted. However, 
unless there is exceeding good communication between the 
dermatologist and other healthcare providers, the authors 
feel it useful to have a baseline screen for ANA titres with 
annual or every two year tests for ANA to reduce the risk 
of other healthcare professionals initiating costly diagnostic 
procedures based upon incidental and clinically unimportant 
laboratory results. 
Cutaneous reactions
Leukocytoclastic vasculitis has been reported in patients 
treated with etanercept. Some instances resolve spontaneously 
while on therapy. Results are mixed on re-challenge with 
instances of recurrence while others are not (Galaria et al 
2000; Mohan et al 2004). The underlying mechanism and 
association are not clear. 
Cases of urticaria have been reported in associated with 
etanercept (Skytta et al 2000). Possibly more uncommon are 
cases of psoriasis induced by treatment of RA with etanercept 
(Sﬁ  kakis et al 2005).
Cardiovascular
Congestive heart failure
We do not know the underlying incidence of congestive 
heart failure (CHF) in the general psoriasis population. 
More speciﬁ  cally, we do not know the incidence of CHF in 
the population of patients with moderate to severe plaque 
psoriasis. There were no cases of CHF in the 6 months 
etanercept-psoriasis studies (Leonardi et al 2003; Papp 2004; 
Papp et al 2005). It has been reported that 51 RA patients 
treated with TNF-antagonists developed CHF (FDA 2003). 
The mean time to onset was 3.5 months post initiation of 
therapy. At least half of the cases had pre-existing risk 
factors for CHF. However, there are data showing that 
polymorphisms in the promoter region of the TNF gene are 
associated with cardiovascular complications (Elahi and 
Matata 2005).
Biologically, there is evidence to support the use of 
TNF-antagonists for the treatment of CHF (Torre-Amione 
et al 2000; Cush 2004c). A study to evaluate 3 months of 
therapy with etanercept for the treatment of New York Heart 
Association (NYHA) III-IV CHF showed a significant 
dose-dependent improvement in left ventricular structure 
and function and a trend towards improvement in patient 
functional status (Bozkurt et al 2001). A study assessing 
etanercept at 25 mg, 50 mg, or 75 mg weekly for the treatment 
of NYHA III-IV CHF was stopped prematurely owing to 
prespeciﬁ  ed stopping rules supporting lack of efﬁ  cacy. There 
was no evidence of worsening of outcome, but neither was 
there relevant beneﬁ  t on rate of death or hospitalization 
(Mann et al 2004).
Subsequently, MedWatch reported 47 patients experiencing 
new or worsening CHF on anti-TNF therapy: 38 developed 
new-onset (26 etanercept, 12 infliximab); 19 had no 
identiﬁ  able risk factors (12 etanercept and 7 inﬂ  iximab); 9 
experienced exacerbation (3 etanercept, 6 inﬂ  iximab) (Kwon 
et al 2003). Of those patients with new onset CHF, 29 were 
receiving treatment for RA, six for Crohn’s Disease, one for 
psoriatic arthritis, one for juvenile RA, and one unknown.
Evidence from Arthritis Research Center Foundation 
registry suggests etanercept may reduce risk of CHF in 
patients with RA compared with patients not receiving anti-
TNF therapy (Wolfe and Michaud 2004a). Overall, heart 
failure was signiﬁ  cantly less common in patients receiving 
anti-TNF therapy than in other patients (p < 0.05). There 
was no increase in heart failure observed among patients 
younger than 50 years.
There is currently insufﬁ  cient evidence to ascribe a causal 
association between etanercept and CHF. Evidence from 
limited clinical studies of patients suffering severe CHF and 
data from long-term registries suggest no association with 
the onset of CHF and the use of etanercept. On the contrary, 
there is evidence supporting a beneﬁ  cial effect on CHF in 
patients treated with etanercept.
Cautionary notes
Wound healing
In a small series of 31 patients with RA undergoing foot or 
ankle surgery, the use of etanercept or inﬂ  iximab (15 of the 31 
patients were treated with standard DMARD therapies) was 
not associated with an increased risk of post-surgical wound 
healing or infection (Bibbo and Goldberg 2004). Nonetheless, 
caution and evaluation of risk-beneﬁ  t must be considered 
when patients on etanercept undergo elective surgery.
Insulin resistance and diabetes
Population studies (Zinman et al 1999) and genetic studies 
(Obayashi et al 2000; Rasmussen et al 2000) suggest TNF-
alpha concentrations may play a pathophysiological role in Therapeutics and Clinical Risk Management 2007:3(2) 253
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and are positively correlated with insulin resistance. Though 
no severe episodes of hypoglycemia were reported in clinical 
studies evaluating etanercept, appropriate precautions are 
advisable when introducing anti-TNF therapy in patients 
with insulin resistance.
Breast feeding and pregnancy
Detectable levels of etanercept are found in breast milk 
(Ostensen and Eigenmann 2004). The clinical signiﬁ  cance 
of this observation is unknown and complicated by the low 
gastric proteolytic activity in preterm infants and newborns 
(Hamosh 1996; Henderson et al 2001).
In mice, TNF plays an essential role in implantation 
(Tartakovsky and Ben-Yair 1991). Elevated levels of TNF-
alpha have been associated with recurrent spontaneous 
abortions and infertility (Daher et al 1999; Murakami 
et al 2002). While there are theoretical concerns regarding 
implantation and ovulation, there is no evidence supporting 
altered fertility in humans treated with etanercept and 
likewise no evidence for embryotoxicity or teratogenicity 
(Khanna et al 2004).
Summary
Characterizing the safety of etanercept in patients with 
psoriasis is neither simple nor complete. Long term risk 
associated with use of etanercept will require vigilance 
(Imperato et al 2004). The identiﬁ  cation of rare events 
requires exposure of tens and hundreds of thousands of 
patients. The current state of information suggests three broad 
categories of concern.
Patients receiving etanercept are more prone to infections. 
The majority of infections are mild: upper respiratory tract 
infections localized cutaneous abscesses, and cold-like 
illnesses. Patients may have increased susceptibility to 
infections by intracellular organisms particularly listeria 
and tuberculsosis. Reactivation of latent infection is not yet 
supportable. Those acquiring tuberculosis are at increased 
risk of presenting with atypical or disseminated infection. 
Patients who become septic and are receiving etanercept are 
at greater risk of fatality than those who are not.
Prior to instituting therapy with etanercept, a review 
of risks should be completed. An outline is provided in 
Table 1. Suggestions for monitoring therapy are outlined in 
Table 2. Precautions should be maintained during therapy 
with routine laboratory testing and patient review with special 
regard to signs and symptoms of infection or adverse effects 
exacerbated by treatment with etanercept. Patients should be 
reminded to discontinue therapy with etanercept when treated 
with antibiotics. Patients should also be aware of the reduced 
efﬁ  cacy of vaccination while on treatment with etanercept.
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